Researchers found preoperative blood glucose levels were associated with hospital length of stay for patients undergoing laparoscopic nephrectomy for RCC.
Real-world data validate recently reported findings from clinical trials.
Rate of disease-free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy.
The approval was based on data from the phase 3 CheckMate-274 trial which evaluated nivolumab as an adjuvant treatment in 699 adults who have undergone radical surgery for invasive urothelial carcinoma at high risk of recurrence.
Vicineum is an investigational locally administered recombinant fusion protein that targets EpCAM antigens on the surface of tumor cells to deliver Pseudomonas Exotoxin A.
The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other VHL-associated tumors.
Sacituzumab govitecan produced responses in all subgroups of patients.
The approval was based on data from the pivotal phase 3 CLEAR (Study 307)/KEYNOTE-581 trial.
Treatment-naïve patients had better outcomes than previously-treated patients.
Decisions of how to proceed when positive surgical margins are found after partial nephrectomy are left to the discretion of the surgeon.
Patients with BCG-unresponsive, non–muscle-invasive bladder cancer who received pembrolizumab had a complete response rate of 41%.
The combination of immune therapy and targeted therapy in biomarker-driven populations does not appear to improve efficacy.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Patients who have ctDNA-positive urothelial carcinoma were found to be at higher risk for disease recurrence than those with a ctDNA-negative status.
RSK4-targeting floxacins could boost the efficacy of chemotherapy.
Platinum-based chemotherapy should remain the standard of care, according to researchers.
Photodynamic diagnosis cystoscopy demonstrates greater sensitivity in the detection of BCG-refractor bladder tumors compared with standard white light cystoscopy.
Researchers in The Netherlands compared the surgical approaches in patients with muscle-invasive or high-risk nonmuscle-invasive bladder cancer.
Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators.
Before PDD TURBT can be adopted into clinical practice, a large pragmatic trial is needed, according to investigators.